Products

Get a quote

We're excited to learn more about your project and provide you with a customized quote tailored to your needs. Please fill out the form below, and we'll get back to you as soon as possible.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mouse Anti-Dengue Virus Type 2 Envelope Protein E Monoclonal Antibody

Cat. No.VD11Y646

Product TypeVeterinary Antibodies

Size

Inquiry Now Add to Inquiry List

Product Overview

BioVenic mouse anti-Dengue virus type 2 envelope protein E monoclonal antibody can be used in ELISA to help researchers detect or develop diagnosis assays of Dengue virus type 2 infection.

Specifications

Application ELISA

Clonality Monoclonal Antibody

Classification Primary Antibody

Clone N29Y84

Host Mouse

Target Species Virus

Species Reactivity Virus

Specificity Dengue Virus Type 2 Envelope Protein E

Isotype IgG1

Immunogen Recombinant Dengue virus type 2 envelope protein E.

Purification Purified by ion exchange chromatography

Conjugation Unconjugated

Buffer Phosphate buffered saline

Physical State Lyophilized

Target Information

The Dengue virus type 2 envelope protein (E protein) is a structural protein that plays a crucial role in the virus's entry into host cells and is a major target for neutralizing antibodies produced by the host immune system. Diagnostic assays often target the E protein, to detect the presence of the virus in samples.

Target Dengue Virus Type 2 Envelope Protein E

Gene ID 9221889

UniProt ID P18356

Shipping and Storage

This product is shipped with dry ice. Store at -20°C on receipt (up to 12 months). Avoid repeated freezing and thawing as this may denature the antibody.

Documents

Datasheet

COA

To request a Certificate of Analysis, please enter the Lot No. in the search box. Note: Certificate of Analysis not available for kits.

The product is for research use only.
Not for commercial, prophylactic, diagnostic, or therapeutic applications.

References

Azevedo, Adriana S., et al. "DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III." PLoS One 6.7 (2011): e20528.